Rallybio Corporation
NASDAQ Capital MarketTotal Valuation
Rallybio Corporation carries a market capitalization of 90.48M, placing it among publicly traded companies globally. Its enterprise value stands at -7.94M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 90.48M |
| Enterprise Value | -7.94M |
Share Statistics
Rallybio Corporation currently has 5.31M shares outstanding.
| Shares Outstanding | 5.31M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Rallybio Corporation trades at a trailing price-to-earnings ratio of 1.99. The price-to-sales ratio is 140.52, and the price-to-book ratio stands at 0.90.
| PE Ratio | 1.99 |
| PS Ratio | 140.52 |
| PB Ratio | 0.90 |
| P/TBV Ratio | 0.90 |
| P/FCF Ratio | 3.42 |
| P/OCF Ratio | 3.40 |
Enterprise Valuation
| EV / Sales | 0.95 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Rallybio Corporation maintains a current ratio of 27.26, meaning it holds 27.3x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 27.26 |
| Quick Ratio | 26.03 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
Rallybio Corporation posts a return on equity of 64.86 and a return on invested capital of -38.00.
| Return on Equity (ROE) | 64.86 |
| Return on Assets (ROA) | 61.12 |
| Return on Invested Capital (ROIC) | -38.00 |
| Return on Capital Employed (ROCE) | 64.83 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
Over the trailing twelve months, Rallybio Corporation has paid 1.32M in income taxes, reflecting an effective tax rate of 2.82.
| Income Tax | 1.32M |
| Effective Tax Rate | 2.82 |
Stock Price Statistics
Rallybio Corporation's stock has gained approximately 282.287% over the past 52 weeks. The 50-day moving average sits at 16.65, while the 200-day moving average is 11.58.
| Beta (5Y) | N/A |
| 52-Week Price Change | 282.287% |
| 50-Day Moving Average | 16.65 |
| 200-Day Moving Average | 11.58 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Rallybio Corporation generated 646,000.00 in revenue and converted that into 45.55M in net income, yielding earnings per share of 7.98. EBITDA reached -27.68M, while operating income came in at -27.72M.
| Revenue | 646,000.00 |
| Gross Profit | N/A |
| Operating Income | -27.72M |
| Pretax Income | 46.88M |
| Net Income | 45.55M |
| EBITDA | -27.68M |
| EBIT | -27.72M |
| Earnings Per Share (EPS) | 7.98 |
Balance Sheet
Total book value stands at 94.50M, with working capital of 93.69M providing operational flexibility.
| Cash & Cash Equivalents | 92.85M |
| Total Debt | N/A |
| Net Debt | -92.85M |
| Equity (Book Value) | 94.50M |
| Book Value Per Share | 17.81 |
| Working Capital | 93.69M |
Cash Flow
Rallybio Corporation produced 26.71M in operating cash flow over the past twelve months.
| Operating Cash Flow | 26.71M |
| Capital Expenditures | N/A |
| Free Cash Flow | 26.71M |
| FCF Per Share | 4.71 |
Margins
Rallybio Corporation operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -4,291.49 and net profit margin of 7,051.24 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | -4,291.49 |
| Pretax Margin | 7,256.19 |
| Profit Margin | 7,051.24 |
| EBITDA Margin | -4,284.83 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -0.16 |
| FCF Yield | 29.26 |
Stock Splits
Rallybio Corporation's most recent stock split took place on February 6, 2026 with a 8:1 split ratio.
| Last Split Date | 2/6/2026 |
| Split Ratio | 8:1 |
Scores
Rallybio Corporation posts an Altman Z-Score of 10.70, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 10.70 |